Posts Tagged ‘ankylosing spondylitis vs reactive arthritis’
Conventional therapies such as chemotherapy and hormonal therapy, but control of the progression of the disease, often associated with side effects. For example, the side effects caused by chemotherapy in cancer range from nausea and hair loss of thrombocytopenia and neutropenia.
Patients often succumb to death due to side effects and cancer.Chemotherapy does not possess the characteristics of the target selectively.Once administered, inducing a systemic action throughout the body that lead to these potential side effects.
Targeted therapies such as monoclonal antibodies have so far shown better efficacy and safety profiles compared with chemotherapy. However, in reality they do not induce complete remission of the disease. Or reduce the signs and symptoms of the disease or slow tumor growth. The inability of these therapies to cure diseases has created significant unmet needs in cancer diseases, diseases of hepatitis, HIV and autoimmune diseases.
Many market Avastin as monoclonal antibodies, rituximab, and Remicade are approved for several indications lead to increased opportunities for patient base for these products. Alemtuzumab, approved B-cell chronic lymphocytic leukemia, is in Phase III clinical trials of multiple sclerosis. REMICADE is approved for the treatment of plaque psoriasis, rheumatoid arthritis, psoriatic arthritis.
Crohn’s disease in adults, pediatric Crohn’s disease, ulcerative colitis and ankylosing spondylitis. REMICADE is also in Phase III clinical trials for the treatment of juvenile rheumatoid arthritis and in Phase II clinical trials for the treatment of sarcoidosis, chronic obstructive pulmonary disease (COPD), cachexia, and asthma.
Enbrel was approved to treat rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.GBI investigation, the leading provider of business intelligence, has released its latest study, “Targeted Therapeutics Advancement in Gene Therapy and Stem Cell Therapy Market to run.”
It provides key information, data, and analyzes the main types of targeted therapies and key pipeline molecules. Report of the whole profile of the key promising therapies in the pipeline. Report a comprehensive analysis of the key M & A and licensing agreements with major companies and analyzes the results of each deal. It also analyzes regulatory strategies in a scenario of gene therapy and stem cell therapy.
Incoming search terms:
- long term effects of ankylosing spondylitis
- what remicade can cause?
- ankylosing spondylitis and anemia
- effects of long term ankylosing spondylitis
- ankylosing spondylitis vs reactive arthritis
- long term effects of ankylosing
- long term effects of anklyosing spondilytis
- LONG TERM EFFECTS OF ANKALOCKINGS SPONDULITUS
- long term ankylosing spondylitis
- is spondylosis hormonal
Reactive arthritis, referred to also as Reiter’s syndrome although this name is lapsing, is an arthritic condition related to infections such as Salmonella in the gastro-intestinal system and Chlamydia in the genito-urinary system. Reactive arthritis has a strong link with a human leucocyte antigen known as HLAB27 which is well known to be related to another arthritic condition called ankylosing spondylitis. This link puts both these conditions into a group classified as seronegative spondyloarthropathies. The arthritis usually occurs with infections such as urethritis or conjunctivitis but can occur also without them.
Once a person has an infection of the genitourinary system or the gastrointestinal system then the arthritis can come on around two to four weeks later, with a respiratory infection with Chlamydia also a possible causative factor. There may be no apparent preceding infection in around ten percent of patients. Many anatomical structures can be affected by the inflammation, including the mucous membrane, the eyes, the joints, the spine, the ligament-bone and tendon-bone junctions and the gastro-intestinal system. Patients with HLAB27 are fifty times more likely to develop reactive arthritis than those without it.
The arthritis can last longer and be more severe if the person has a strong history in the family or they are HLAB27 positive. Of those having an infection of the gut between one and four percent may develop a reactive arthritis, but this varies greatly even with the same biological agent responsible. It is not understood how the host body and the antigen react to cause the arthritic condition and the samples of joint fluids do not exhibit the infectious organisms. Antibodies have been isolated in the joints and it is possible an inflammatory condition mediated by the immune system is implicated in the development of this condition.
The self limiting nature of this kind of arthritis means that the condition settles down over a 3-12 month period whether the severity of the symptoms is greater or lower. The chance of the condition recurring is significant, with a higher incidence if a patient is positive for HLAB27, and a new episode is potentially triggered by infections or other agents. The arthritic process can be mild or can cause destructive and disabling changes in the joints in a small group of fifteen percent of sufferers. The usual age range for onset of this condition is between 20 and 40 years, gut infections giving a 50:50 male to female ratio and urogenital infections giving a 9 to 1 ratio.
Reactive arthritis usually comes on quickly as an acute presentation with patients presenting with tiredness, high temperature and a feeling of being unwell. Lower extremity arthritis of a few joints, arranged non symmetrically (unlike rheumatoid arthritis) is common. Heel pain from inflammation of the insertion of the Achilles tendon into the heel bone is common and low back pain is present in half of the patients. Lower limb joints involved in weight bearing are typically affected, with more severely affected patients exhibiting hands and feet symptoms. Back pain symptoms are commonly reported but examination shows few findings apart from a reduction in lumbar flexion.
Reactive arthritis treatment is determined by how difficult the arthritic symptoms are for the patient, with a mainstay of treatment being non-steroidal anti-inflammatory drugs which are taken regularly to keep up a level of anti-inflammatory action. The maintenance and restoration of muscle power, control of pain and protection of joint ranges of motion can be effected by referral to physiotherapy. Intra-articular injections with corticosteroids are a useful treatment and can give long term relief of an inflamed joint. If anti-inflammatory drugs are not effective then systemic corticosteroids can be given and while antibiotic drugs may be prescribed at times they do not affect the disease course.
Chronic and ongoing joint arthritis and poorly limited inflammatory reactions may mean a rheumatologist will prescribe drugs known as DMARDS or disease modifying anti-rheumatoid drugs. These have been tested on conditions such as rheumatoid arthritis or ankylosing spondylitis but their usefulness in reactive arthritis has not been shown. Typical examples are methotrexate and sulphasalazine. The newer biological drug treatments have been effective in some conditions but have not yet been shown to be useful in this condition.
Incoming search terms:
- gastric arthritis
- reiters syndrome and ankylosing spondylitis
- ankylosing spondylitis what age does it usually occur
- does arthritis develop quickly
- does rhemitoid arthritis come on quickly
- why is ankylosing spondilitis disabling
- reiters syndrome and ankylosing spondylitis and remicade
- link between gastric bypass and arthritis
- is ankylosing spondylitis a reactive arthritis